Colorectal carcinoma is one of the most frequent malignancies in Europe and the second most common malignancy in the United States, with more than 150,000 new cases diagnosed in the United States and 60,000 deaths per year (Boring et al., 1991) . Surgical resection and more recently adjuvant chemotherapy have become the standard approach for early stage disease (Grem, 1991) . However, approximately 20% of patients have metastases at the time of diagnosis, and nearly 50% of patients will eventually develop metastatic disease (Kemeny. 1987 ).
Systemic chemotherapy with 5-fluorouracil (5-FU)-based therapy has been standard treatment for the last 30 years with a response rate of 20% (Heiderberg et al., 1957; Hansen, 1990) . Newer therapeutic regimens are almost always compared with 5-FU. However, no meaningful survival differences have been demonstrated when compared with no treatment. Many 5-FU-containing combinations have been investigated with poor overall response rates ranging from 8% to 37% (Valone et al., 1989) . Recently, biochemical modulation of 5-FU with leucovorin has been shown to improve the overall response rates compared with 5-FU alone (Erlichman et al., 1988; Petrelli et al., 1989; Poon et al., 1989; Doroshow et al., 1990) . Only few studies, however, have shown improvement in survival (Erlichman et al., 1988; Petrelli, 1989; Hansen, 1990) . A variety of other single agents have only occasionally produced some tumour regression (Coehn et al., 1989; Bruckner, 1991) . Since few truly effective treatment options are available for advanced colorectal carcinoma, new and more effective agents are urgently needed.
Paclitaxel (Taxol), extracted from the Pacific Yew Taxus brevifolia (Wani et al., 1971) , has been found to have significant activity in several human malignancies, including refractory ovarian cancer and breast cancer (McGuire et al., 1989; Holmes et al., 1991) . Docetaxel (Taxotere) is a taxoid semisynthesised from a precursor extracted from the needles of the European yew, Taxus baccata (Mangatal et al., 1989 (Ringel, 1991; Horwitz, 1992 (Geran et al., 1972) , and the human tumour xenograft CX-1 (Harrison et al., 1992 In one patient (3%) with liver metastases a complete response lasting 54 weeks was obtained, two patients (6%) (95% confidence limits 0-14%) attained a partial response (PR) in liver metastases, nine (27%) patients had stable disease and 21 (64%) progressed. The median time to progression in the evaluable patients was 1.5 months and the median survival was 7.5 months. A total of 118 cycles of docetaxel were administered. The median number of cycles per patient was 2 (range 1-15). Twenty-seven patients had no dose reduction. Twelve patients received 75 mg m-in 26 cycles, and two of these patients subsequently also received 55 mg m2 docetaxel in three cycles. Reasons for dose reduction were haematological toxicity (seven cycles), nonhaematological (mostly skin) toxicity (20 cycles) or both (two cycles). The most frequent reason for a patient to go off study was tumour progression.
Toxicity
The most important side-effects are described in Table II 
Discusio
The toxicities observed with docetaxel in this phase II study were similar to those observed in the treatment of patients with other solid tumours (Verweij et al., 1994) . Reversible alopecia was practically universal and occurred within 2-4 weeks after the start of therapy. Hypersensitivity reactions, as have been observed with other taxoids, were relatively infrequent and were rarely severe despite the fact that no routine premedication was used. Premedication including corticosteroids and antihistamines further reduces the incidence of these reactions (Schrijvers et al.. 1993) . Other toxicities were similar to those observed with paclitaxel. Additional toxcicities included a pruritic skin eruption and peripheral oedema. Skin toxicity consisted of erythema, desquamation and infrequent exfoliation or presented as nail toxicity with calcification and onycholysis. These toxicities were not reduced by the routine use of corticosteroids (Wanders et al., 1993) . Fluid retention was most probably related to the cumulative dose of docetaxel, occurring infrequently at cumulative doses below 400 mg m-' (Wanders et al., 1993) .
In phase II studies docetaxel has already been shown to have anti-tumour activity in breast cancer, non-small cell lung cancer, ovarian cancer. soft-tissue sarcoma, head and neck cancer, gastric cancer and melanoma (Verweij et al., 1994) . No activity was seen in renal cancer (Bruntsch et al., 1993) . Based upon the results of this study and the study of Pazdur et al. (1994) , docetaxel, like pacitaxel, has minimal activity in the treatment of colorectal carcinoma. One mechanism conferring resistance to docetaxel and paclitaxel is the multidrug resistance P-glycoprotein, although the clinical relevance of this in colorectal cancer is uncertain (Lehnert et al., 1992) . Treatment of advanced colorectal carcinoma will require further study with new agents in view of its insensitivity to most available cytotoxic drugs.
